The appeal stay provides a temporary reprieve, but the fundamental gap between $8M market cap and $50M MVLS requirement makes compliance nearly impossible. Expect eventual delisting and OTC trading. Short sellers may target the stock ahead of the May 29 suspension date if appeal is denied. Monitor for any reverse stock split or capital restructuring plan filed with the appeal.
Price Chart
Executive Summary
Liminatus Pharma received a Nasdaq delisting notice after failing to regain compliance with the $50M market value of listed securities (MVLS) and $15M market value of publicly held shares (MVPHS) requirements. The company intends to appeal, which will stay the suspension pending a hearing, but the risk of eventual delisting is high given the $8M market cap.
Key Facts
- Received delisting notice on May 20, 2026 for failure to comply with MVLS ($50M) and MVPHS ($15M) rules.
- Appeal must be requested by May 27, 2026; trading suspension would begin May 29, 2026 without a stay.
- Company intends to appeal, which will stay suspension pending a Nasdaq Hearings Panel decision.
- Market cap is only $8M, far below the $50M MVLS threshold, making compliance extremely unlikely.
Financial Impact
Delisting would remove Nasdaq listing and registration, severely impairing liquidity and access to capital. Market cap is $8M vs. $50M MVLS requirement.
Risk Factors
- Nasdaq may deny the appeal, leading to immediate suspension and delisting.
- Delisting would trigger defaults on debt covenants and force conversion of convertible instruments.
- OTC trading after delisting typically results in severe liquidity and price deterioration.
- Company may need to raise dilutive capital at distressed levels to attempt compliance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299867 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 10w ago | 8-K | $0.1117 $0.0678 | ▲ +39.30% | ▲ +38.46% | $2.89 (−2487.29%) |
Jul 6, 2026 16w ago | 8-K | $0.1426 $0.1137 | ▲ +20.27% | ▲ +21.12% | $2.89 (−1926.65%) |
Jun 23, 2026 18w ago | S-1 | $0.1031 $0.1187 | ▲ +15.13% | ▲ +14.46% | $2.89 (+2703.10%) |
May 21, 2026 22w ago | Press Release | $0.1690 $0.1089 | ▲ +35.56% | ▲ +34.15% | $2.89 (−1610.06%) |
Mar 17, 2026 32w ago | Press Release | $0.2300 $0.1860 | ▼ −19.13% | ▼ −23.43% | $2.89 (+1156.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers